In the absence of the study by Mhawech-Fauceglia, the estimated pooled HR indicated that the high CD8+/FoxP3+ ratio was associated with improved OS/DSS in ovarian cancer patients (Figure 6D; HR, 0.61; 95%CI, 0.41-0.92; PHR=0.02; I2=75.5%; random effects model). This evidence concerns the gene FOXP3 and ovarian cancer.